Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Gustave Roussy

Villejuif, 94805, FranceNot linked to an institution yet

116running trials
57closed trials

The trials here

What the 173 trials at this site are about, from their registry records.

Conditions: Lung cancer40 trials
Childhood cancers21 trials
Ovarian cancer21 trials
Pancreatic cancer21 trials
Head and neck cancer18 trials
Sarcoma18 trials
Colorectal cancer17 trials
Liver and biliary tract cancer14 trials
Prostate cancer12 trials
Melanoma11 trials
Kidney cancer9 trials
Bladder cancer8 trials
and 25 more
Phase: Phase 256 trials
Phase 335 trials
Phase 1/225 trials
Phase 113 trials
Phase 2/35 trials
Phase 42 trials
Status: Recruiting65 trials
Completed40 trials
Active, not recruiting32 trials
Not yet recruiting19 trials
Terminated16 trials
Withdrawn1 trial
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris56 trials
UNICANCER16 trials
Eli Lilly and Company9 trials
ARCAGY/ GINECO GROUP8 trials
Hoffmann-La Roche8 trials
and 51 more

Running trials

Not yet recruiting
Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma
NCT07802652· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Antoine ITALIANO, MD, PhD
Not yet recruiting
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
NCT07544225· Phase 1· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Cristina CASTILLA-LLORENTE
Not yet recruiting
Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas
NCT07924384· Institut Curie· Source
Contact: Lucy METAYER, MD (principal investigator)
Not yet recruiting
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
2026-527617-29-00· Phase 3· Systimmune Inc.· Source
Recruiting
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Nathalie GASPAR, Docteur
Not yet recruiting
Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.
NCT07802847· Phase 4· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Arnaud BAYLE
Not yet recruiting
Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
NCT07463768· Phase 2· French Innovative Leukemia Organisation· Source
Contact: Stephane DE BOTTON
Not yet recruiting
Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer
NCT07591467· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Alice BERNARD-TESSIER, MD.
Not yet recruiting
Adjuvant Trial in Pancreatic Neuroendocrine Tumors
NCT07591493· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Matthieu FARON, MD
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644· Phase 3· SystImmune Inc.· Source
Contact: Pernelle Lavaud (principal investigator)
Not yet recruiting
Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer
NCT07637851· Phase 1/2· ARCAGY/ GINECO GROUP· Source
Contact: Alexandra LEARY (principal investigator)
Not yet recruiting
KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer
NCT07622017· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Eric Deutsch, MD, PhD
Recruiting
Cohort of Patients With Chronic Myelomonocytic Leukemia
NCT07512882· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Christophe WILLEKENS
Recruiting
Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer
NCT07436312· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Bruno Raynard, MD
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655· Phase 1· Pfizer· Source
Recruiting
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
NCT07549321· Phase 2/3· Renaissance Pharma Ltd.· Source
Contact: Pablo Berlanga, Dr
Recruiting
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738· Phase 1/2· Orion Corporation, Orion Pharma· Source
Contact: Antoine Hollebecque, MD
Recruiting
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
NCT07483983· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Yohann Loriot, MD, PhD
Recruiting
Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
NCT06907095· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Suzette Delaloge, MD
Recruiting
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
NCT07303387· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Sophie Postel-Vinay, MD, PhD
Recruiting
Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma
NCT07529873· Phase 2· Groupe Oncologie Radiotherapie Tete et Cou· Source
Contact: Caroline EVEN, Dr
Not yet recruiting
Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.
NCT07111117· Phase 2· Institut Curie· Source
Contact: Desiree Deandreis, MD
Recruiting
Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
NCT07230613· Phase 2· UNICANCER· Source
Contact: Caroline ROBERT, MD, PhD
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Contact: Cyril Roussel-simonin (principal investigator)
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Contact: Yohann Loriot (principal investigator)
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559· Phase 2· ALX Oncology Inc.· Source
Contact: Cheng Quah, MD
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674· Phase 3· Amgen· Source
Recruiting
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
NCT07001618· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Lisa DE ROSA, MD, PhD
Recruiting
A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer
NCT07159451· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Jean Zeghondy, MD
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· Phase 2/3· Pfizer· Source
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Yohann Loriot, Site 0001
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
NCT06840782· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Antonin LÉVY, MD
Recruiting
STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue
NCT06505590· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Ines VAZ-LUIS, MD
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113· Phase 1· Amgen· Source
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755· Phase 2/3· Exelixis· Source
Contact: Exelixis Clinical Trials
Recruiting
Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
NCT07016230· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Yohann Loriot, MD, PhD
Recruiting
A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial
NCT06786234· Phase 2· Step Pharma, SAS· Source
Contact: Carol M MacLean, PhD
Recruiting
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
NCT06934057· Phase 4· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Maxime FRELAUT, MD
Not yet recruiting
Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood
NCT06957132· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Brice Fresneau, MD, PhD
Recruiting
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
NCT06332274· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Antoine ITALIANO, MD
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Contact: Fabrice Barlesi (principal investigator)
Recruiting
Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma
NCT06551272· Phase 2· Center Eugene Marquis· Source
Contact: Valérie JOLAINE
Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287· Phase 1/2· Bristol-Myers Squibb· Source
Contact: David Planchard, Site 0041
Not yet recruiting
Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)
NCT06681038· Phase 2· Institut Cancerologie de l'Ouest· Source
Contact: Isabelle SOURROUILLE, MD
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245· Phase 3· OSE Immunotherapeutics· Source
Contact: Caroline Chevalier, MSc, MPH
Recruiting
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
NCT07334301· Phase 1/2· University of Birmingham· Source
Recruiting
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117· Phase 1/2· Pierre Fabre Medicament· Source
Contact: Medical Officer
Active, not recruiting
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320· Phase 3· Revolution Medicines, Inc.· Source
Active, not recruiting
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
NCT06813573· Gustave Roussy, Cancer Campus, Grand Paris· Source

Showing 50 of 116.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer19 recruiting
Childhood cancers14 recruiting
Colorectal cancer10 recruiting
Pancreatic cancer10 recruiting
Ovarian cancer8 recruiting
Sarcoma8 recruiting
Head and neck cancer7 recruiting
Kidney cancer6 recruiting
Prostate cancer6 recruiting
Bladder cancer4 recruiting
Liver and biliary tract cancer4 recruiting
Melanoma4 recruiting
Neuroblastoma4 recruiting
Neuroendocrine tumours4 recruiting
Endometrial cancer3 recruiting
Metastatic breast cancer3 recruiting
Acute myeloid leukaemia2 recruiting
Gastric and oesophageal cancer2 recruiting
Mesothelioma2 recruiting
Triple-negative breast cancer2 recruiting
Chronic myeloid leukaemia1 recruiting
Dermatomyositis and polymyositis (myositis)1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Follicular lymphoma1 recruiting
Hearing loss1 recruiting
Lupus (SLE)1 recruiting
Myeloproliferative neoplasms1 recruiting
Rheumatoid arthritis1 recruiting
Systemic sclerosis (scleroderma)1 recruiting

Closed trials

Terminated
Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
NCT07061080· Phase 2· Grupo Espanol de Tumores Neuroendocrinos· Source
Withdrawn
Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab
NCT06116578· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer
NCT05075577· Phase 1/2· Essa Pharma Inc.· Source
Completed
Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer
NCT06660147· ARCAGY/ GINECO GROUP· Source
Terminated
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
NCT05908786· Phase 1/2· Hoffmann-La Roche· Source
Terminated
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
NCT05625087· Phase 2· UNICANCER· Source
Completed
A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer
NCT05846594· Hoffmann-La Roche· Source
Completed
Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer
NCT06007092· Phase 1/2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Terminated
A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
NCT05119010· Gustave Roussy, Cancer Campus, Grand Paris· Source
Terminated
Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma
NCT05705791· Gustave Roussy, Cancer Campus, Grand Paris· Source
Terminated
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316· Phase 2· Agenus Inc.· Source
Terminated
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05325866· Phase 1/2· Amgen· Source
Terminated
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
NCT05256381· Phase 2· SOTIO Biotech AG· Source
Terminated
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
NCT05269355· Phase 2/3· PTC Therapeutics· Source
Completed
A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors (EVICTION-2)
NCT04243499· Phase 1/2· Imcheck Therapeutics· Source
Completed
Optimization of an Online Stepwise Therapeutic Device Based on a Cognitive-behavioral Approach for Cancer Patients With Insomnia
NCT05977062· Gustave Roussy, Cancer Campus, Grand Paris· Source
Terminated
Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
NCT05180006· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC
NCT04725396· UNICANCER· Source
Terminated
Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
NCT04779151· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence
NCT05071001· Gustave Roussy, Cancer Campus, Grand Paris· Source
Terminated
Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer
NCT04450836· Phase 2· UNICANCER· Source
Completed
A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)
2023-506156-25-00· Phase 1/2· Institut Gustave Roussy· Source
Completed
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
NCT04238819· Phase 1/2· Eli Lilly and Company· Source
Terminated
Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
NCT04826198· Phase 1/2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation
NCT04233021· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Completed
A Study of DF6002 Alone and in Combination With Nivolumab
NCT04423029· Phase 1· Dragonfly Therapeutics· Source
Completed
A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
NCT04300647· Phase 2· Hoffmann-La Roche· Source
Completed
Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer
NCT04304924· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
NCT04068181· Phase 2· Amgen· Source
Completed
Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis
NCT04132960· Phase 2· UNICANCER· Source
Terminated
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
NCT04082936· Phase 1/2· IGM Biosciences, Inc.· Source
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597· Phase 1/2· CellCentric Ltd.· Source
Contact: Tomasz Knurowski, PhD
Completed
Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma
NCT04267146· Phase 1/2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
Her2-positive Lung Cancer Treated With Dedicated Drug
NCT03845270· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Completed
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
NCT03596866· Phase 3· Takeda· Source
Completed
UTOLA: UTerin OLAparib
NCT03745950· Phase 2· ARCAGY/ GINECO GROUP· Source
Completed
Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer
NCT03598270· Phase 3· Grupo Español de Investigación en Cáncer de Ovario· Source
Completed
Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
NCT03579394· ARCAGY/ GINECO GROUP· Source
Terminated
Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction
NCT03165292· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix
NCT03556839· Phase 3· Grupo Español de Investigación en Cáncer de Ovario· Source
Completed
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
NCT03353831· Phase 3· AGO Research GmbH· Source
Completed
Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab
NCT03612791· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Terminated
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
NCT03412058· UNICANCER· Source
Completed
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
NCT03244956· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer
NCT03314324· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer
NCT03249142· Phase 1/2· ARCAGY/ GINECO GROUP· Source
Completed
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
NCT03212469· Phase 1/2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
NCT03037385· Phase 1/2· Hoffmann-La Roche· Source
Completed
Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours
NCT02992912· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab
NCT02891824· Phase 3· ARCAGY/ GINECO GROUP· Source

Showing 50 of 57.

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error